Literature DB >> 21841210

Improved tumour response prediction with equivalent uniform dose in pre-clinical study using direct intratumoural infusion of liposome-encapsulated ¹⁸⁶Re radionuclides.

Brian A Hrycushko1, Steve Ware, Shihong Li, Ande Bao.   

Abstract

Crucial to all cancer therapy modalities is a strong correlation between treatment and effect. Predictability of therapy success/failure allows for the optimization of treatment protocol and aids in the decision of whether additional treatment is necessary to prevent tumour progression. This work evaluated the relationship between cancer treatment and effect for intratumoural infusions of liposome-encapsulated ¹⁸⁶Re to head and neck squamous cell carcinoma xenografts of nude rats. Absorbed dose calculations using a dose-point kernel convolution technique showed significant intratumoural dose heterogeneity due to the short range of the beta-particle emissions. The use of three separate tumour infusion locations improved dose homogeneity compared to a single infusion location as a result of a more uniform radioactivity distribution. An improved dose-response correlation was obtained when using effective uniform dose (EUD) calculations based on a generic set of radiobiological parameters (R² = 0.84) than when using average tumour absorbed dose (R² = 0.22). Varying radiobiological parameter values over ranges commonly used for all types of tumours showed little effect on EUD calculations, which suggests that individualized parameter use is of little significance as long as the intratumoural dose heterogeneity is taken into consideration in the dose-response relationship. The improved predictability achieved when using EUD calculations for this cancer therapy modality may be useful for treatment planning and evaluation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841210      PMCID: PMC3164288          DOI: 10.1088/0031-9155/56/17/016

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  27 in total

1.  Viability of the EUD and TCP concepts as reliable dose indicators.

Authors:  M A Ebert
Journal:  Phys Med Biol       Date:  2000-02       Impact factor: 3.609

Review 2.  Biological factors influencing optimum fractionation in radiation therapy.

Authors:  J F Fowler
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

3.  Determination of subcutaneous tumor size in athymic (nude) mice.

Authors:  M M Tomayko; C P Reynolds
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Direct intratumoral infusion of liposome encapsulated rhenium radionuclides for cancer therapy: effects of nonuniform intratumoral dose distribution.

Authors:  Brian A Hrycushko; Shihong Li; Beth Goins; Randal A Otto; Ande Bao
Journal:  Med Phys       Date:  2011-03       Impact factor: 4.071

5.  Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.

Authors:  George Sgouros; Shannon Squeri; Ase M Ballangrud; Katherine S Kolbert; Jerrold B Teitcher; Katherine S Panageas; Ronald D Finn; Chaitanya R Divgi; Steven M Larson; Andrew D Zelenetz
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

Review 6.  Targeting of radio-isotopes for cancer therapy.

Authors:  Diane E Milenic; Martin W Brechbiel
Journal:  Cancer Biol Ther       Date:  2004-04-03       Impact factor: 4.742

7.  On cold spots in tumor subvolumes.

Authors:  Wolfgang A Tomé; Jack F Fowler
Journal:  Med Phys       Date:  2002-07       Impact factor: 4.071

8.  Beta dose-rate distributions in microscopic spherical tumors for intraperitoneal radioimmunotherapy.

Authors:  Alasdair Syme; Steve McQuarrie; B Gino Fallone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-08-01       Impact factor: 7.038

9.  Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation.

Authors:  B Maciejewski; H R Withers; J M Taylor; A Hliniak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-03       Impact factor: 7.038

10.  Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.

Authors:  George Sgouros; Katherine S Kolbert; Arif Sheikh; Keith S Pentlow; Edward F Mun; Axel Barth; Richard J Robbins; Steven M Larson
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

View more
  5 in total

1.  Impact of PET and MRI threshold-based tumor volume segmentation on patient-specific targeted radionuclide therapy dosimetry using CLR1404.

Authors:  Abigail E Besemer; Benjamin Titz; Joseph J Grudzinski; Jamey P Weichert; John S Kuo; H Ian Robins; Lance T Hall; Bryan P Bednarz
Journal:  Phys Med Biol       Date:  2017-07-06       Impact factor: 3.609

2.  Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

Authors:  Abigail E Besemer; Joseph J Grudzinski; Jamey P Weichert; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-10-23       Impact factor: 3.099

3.  Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging.

Authors:  Shihong Li; Beth Goins; Lujun Zhang; Ande Bao
Journal:  Bioconjug Chem       Date:  2012-05-22       Impact factor: 4.774

4.  Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma.

Authors:  Kohei Hanaoka; Makoto Hosono; Yoichi Tatsumi; Kazunari Ishii; Sung-Woon Im; Norio Tsuchiya; Kenta Sakaguchi; Itaru Matsumura
Journal:  EJNMMI Res       Date:  2015-03-14       Impact factor: 3.138

Review 5.  Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine.

Authors:  Francis Man; Peter J Gawne; Rafael T M de Rosales
Journal:  Adv Drug Deliv Rev       Date:  2019-06-03       Impact factor: 15.470

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.